Access the full text.
Sign up today, get DeepDyve free for 14 days.
Face mask use by the general public for limiting the spread of the COVID-19 pandemic is controversial, though increasingly recommended, and the potential of this intervention is not well understood. We develop a compartmental model for assessing the community- wide impact of mask use by the general, asymptomatic public, a portion of which may be asymptomatically infectious. Model simulations, using data relevant to COVID-19 dynamics in the US states of New York and Washington, suggest that broad adoption of even rela- tively ineﬀective face masks may meaningfully reduce community transmission of COVID-19 and decrease peak hospitalizations and deaths. Moreover, mask use decreases the eﬀective transmission rate in nearly linear proportion to the product of mask eﬀectiveness (as a fraction of potentially infectious contacts blocked) and coverage rate (as a fraction of the general population), while the impact on epidemiologic outcomes (death, hospitalizations) is highly nonlinear, indicating masks could synergize with other non-pharmaceutical measures. Notably, masks are found to be useful with respect to both preventing illness in healthy per- sons and preventing asymptomatic transmission. Hypothetical mask adoption scenarios, for Washington and New York state, suggest that immediate near universal (80%) adoption of moderately (50%) eﬀective masks could prevent on the order of 17–45% of projected deaths over two months in New York, while decreasing the peak daily death rate by 34–58%, ab- sent other changes in epidemic dynamics. Even very weak masks (20% eﬀective) can still be useful if the underlying transmission rate is relatively low or decreasing: In Washington, where baseline transmission is much less intense, 80% adoption of such masks could reduce mortality by 24–65% (and peak deaths 15–69%), compared to 2–9% mortality reduction in New York (peak death reduction 9–18%). Our results suggest use of face masks by the gen- eral public is potentially of high value in curtailing community transmission and the burden of the pandemic. The community-wide beneﬁts are likely to be greatest when face masks are used in conjunction with other non-pharmaceutical practices (such as social-distancing), and when adoption is nearly universal (nation-wide) and compliance is high. 1 Introduction Under the ongoing COVID-19 pandemic (caused by the SARS-CoV-2 coronavirus), recommen- dations and common practices regarding face mask use by the general public have varied greatly email firstname.lastname@example.org arXiv:2004.03251v1 [q-bio.PE] 7 Apr 2020 and are in rapid ﬂux: Mask use by the public in public spaces has been controversial in the US, although as of April 3, 2020, the US Centers for Disease Control and Prevention (CDC) is recommending the public wear cloth masks. Public mask use is far more prevalent in many Asian countries, which have longer experience with novel coronavirus epidemics; public mask use may have been eﬀective at limiting community spread during the 2003 SARS epidemic [1, 2], and widespread mask use is a prominent feature of the relatively successful COVID-19 response in Taiwan , for example. Masks have also been suggested as method for limiting community transmission by asymptomatic or at least clinically undetected carriers , who may be a major driver of transmissions of COVID-19 . Various experimental studies suggest that masks may both protect the wearer from acquiring various infections [10, 9] or transmitting infection . Medical masks (i.e., surgical masks and N95 respirators) in healthcare workers appear to consistently protect against respiratory infection under metanalysis [4, 3], although clinical trials in the community have yielded more mixed results [6, 7, 8]. While medical-grade masks should be prioritized for healthcare providers, homemade cloth masks may still aﬀord signiﬁcant, although variable and generally lesser, protection [12, 9], but clinical trials in the community remain lacking. Given the ﬂux in recommendations, and uncertainty surrounding the possible community- wide impact of mass face masks (especially homemade cloth masks) on COVID-19 trans- mission, we have developed a multi-group Kermack-McKendrick-type compartmental mathe- matical model, extending prior work geared towards modeling the COVID-19 pandemic (e.g. [38, 39, 34]), as well as models previously used to examine masks in a potential inﬂuenza pandemic [36, 37]. This initial framework suggests that masks could be eﬀective even if imple- mented as a singular intervention/mitigation strategy, but especially in combination with other non-pharmaceutical interventions that decrease community transmission rates. Whether masks can be useful, even in principle, depends on the mechanisms for transmission for SARS-CoV-2, which are likely a combination of droplet, contact, and possible airborne (aerosol) modes. The traditional model for respiratory disease transmission posits infection via infectious droplets (generally 5–10 µ m) that have a short lifetime in the air and infect the upper respiratory tract, or ﬁner aerosols, which may remain in the air for many hours , with ongoing uncertainties in the relative importance of these modes (and in the conceptual model itself ) for SARS-CoV-2 transmission [45, 41]. The WHO  has stated that SARS-CoV-2 transmission is primarily via coarse respiratory droplets and contact routes. An experimental study  using a nebulizer found SARS-CoV-2 to remain viable in aerosols (<5 µ m) for three hours (the study duration), but the clinical relevance of this setup is debatable . One out of three symptomatic COVID-19 patients caused extensive environmental contamination in , including of air exhaust outlets, though the air itself tested negative. Face masks can protect against both coarser droplet and ﬁner aerosol transmission, though N95 respirators are more eﬀective against ﬁner aerosols, and may be superior in preventing droplet transmission as well . Metanalysis of studies in healthy healthcare providers (in whom most studies have been performed) indicated a strong protective value against clinical and respiratory virus infection for both surgical masks and N95 respirators . Case control data from the 2003 SARS epidemic suggests a strong protective value to mask use by community members in public spaces, on the order of 70% [1, 2]. Experimental studies in both humans and manikins indicate that a range of mask provide at least some protective value against various infectious agents [12, 9, 14, 13, 42]. Medical masks were potentially highly eﬀective as both source control and primary prevention under tidally breathing and coughing conditions in manikin studies [10, 11], with higher quality masks (e.g. N95 respirator vs. surgical mask) oﬀering greater protection . It is largely unknown to what degree homemade masks (typically made from cotton, teacloth, or other polyesther ﬁbers) may 2 protect against droplets/aerosols and viral transmission, but experimental results by Davies et al.  suggest that while the homemade masks were less eﬀective than surgical mask, they were still markedly superior to no mask. A clinical trial in healthcare workers  showed relatively poor performance for cloth masks relative to medical masks. Mathematical modeling has been inﬂuential in providing deeper understanding on the trans- mission mechanisms and burden of the ongoing COVID-19 pandemic, contributing to the devel- opment of public health policy and understanding. Most mathematical models of the COVID-19 pandemic can broadly be divided into either population-based, SIR (Kermack-McKendrick)- type models, driven by (potentially stochastic) diﬀerential equations [38, 20, 34, 22, 21, 23, 31, 26, 32, 24, 33], or agent-based models [39, 28, 25, 27, 30], in which individuals typically interact on a network structure and exchange infection stochastically. One diﬃculty of the latter ap- proach is that the network structure is time-varying and can be diﬃcult, if not impossible, to construct with accuracy. Population-based models, alternatively, may risk being too coarse to capture certain real-world complexities. Many of these models, of course, incorporate features from both paradigms, and the right combination of dynamical, stochastic, data-driven, and network-based methods will always depend on the question of interest. In , Li et al. imposed a metapopulation structure onto an SEIR-model to account for travel between major cities in China. Notably, they include compartments for both documented and undocumented infections. Their model suggests that as many as 86% of all cases went un- detected in Wuhan before travel restrictions took eﬀect on January 23, 2020. They additionally estimated that, on a per person basis, asymptomatic individuals were only 55% as contagious, yet were responsible for 79% of new infections, given their increased prevalence. The impor- tance of accounting for asymptomatic individuals has been conﬁrmed by other studies (, ). In their model-based assessment of case-fatality ratios, Verity et al.  estimated that 40–50% of cases went unidentiﬁed in China, as of February 8, 2020, while in the case of the Princess Diamond cruise ship, 46.5% of individuals who tested positive for COVID-19 were asymptomatic . Further, Calaﬁore et al. , using a modiﬁed SIR-model, estimated that, on average, cases in Italy went underreported by a factor of 63, as of March 30, 2020. Several prior mathematical models, motivated by the potential for pandemic inﬂuenza, have examined the utility of mask wearing by the general public. These include a relatively simple modiﬁcation of an SIR-type model by Brienen et al. , while Tracht et al.  considered a more complex SEIR model that explicitly disaggregated those that do and do not use masks. The latter concluded that, for pandemic H1N1 inﬂuenza, modestly eﬀective masks (20%) could halve total infections, while if masks were just 50% eﬀective as source control, the epidemic could be essentially eliminated if just 25% of the population wore masks. We adapt these previously developed SEIR model frameworks for transmission dynamics to explore the potential community-wide impact of public use of face masks, of varying eﬃcacy and compliance, on the transmission dynamics and control of the COVID-19 pandemic. In particular, we develop a two-group model, which stratiﬁes the total population into those who habitually do and do not wear face masks in public or other settings where transmission may occur. This model takes the form of a deterministic system of nonlinear diﬀerential equations, and explicitly includes asymptomatically-infectious humans. We examine mask eﬀectiveness and coverage (i.e., fraction of the population that habitually wears masks) as our two primary parameters of interest. We explore possible nonlinearities in mask coverage and eﬀectiveness and the interaction of these two parameters; we ﬁnd that the product of mask eﬀectiveness and coverage level strongly predicts the eﬀect of mask use on epidemiologic outcomes. Thus, homemade cloth masks are best deployed en masse to beneﬁt the population at large. There is also a potentially strong nonlinear eﬀect of mask use on epidemiologic outcomes of cumulative death and peak 3 hospitalizations. We note a possible temporal eﬀect: Delaying mass mask adoption too long may undermine its eﬃcacy. Moreover, we perform simulated case studies using mortality data for New York and Washington state. These case studies likewise suggest a beneﬁcial role to mass adoption of even poorly eﬀective masks, with the relative beneﬁt likely greater in Washington state, where baseline transmission is less intense. The absolute potential for saving lives is still, however, greater under the more intense transmission dynamics in New York state. Thus, early adoption of masks is useful regardless of transmission intensities, and should not be delayed even if the case load/mortality seems relatively low. In summary, the beneﬁt to routine face mask use by the general public during the COVID-19 pandemic remains uncertain, but our initial mathematical modeling work suggests a possible strong potential beneﬁt to near universal adoption of even weakly eﬀective homemade masks that may synergize with, not replace, other control and mitigation measures. 2 Methods 2.1 Baseline mathematical models 2.1.1 Model with no mask use We consider a baseline model without any mask use to form the foundation for parameter estimation and to estimate transmission rates in New York and Washington state; we also use this model to determine the equivalent transmission rate reductions resulting from public mask use in the full model. We use a deterministic susceptible, exposed, symptomatic infectious, hospitalized, asymp- tomatic infectious, and recovered modeling framework, with these classes respectively denoted S(t), E(t), I(t), H(t), A(t), and R(t); we also include D(t) to track cumulative deaths. We assume that some fraction of detected infectious individuals progress to the hospitalized class, H(t), where they are unable to pass the disease to the general public; we suppose that some fraction of hospitalized patients ultimately require critical care (and may die) , but do not explicitly disaggregate, for example, ICU and non-ICU patients. Based on these assumptions and simpliﬁcations, the basic model for the transmission dynamics of COVID-19 is given by the following deterministic system of nonlinear diﬀerential equations: dS S = −β(t)(I + ηA) , (2.1) dt N dE S = β(t)(I + ηA) − σE, (2.2) dt N dI = ασE − φI − γ I, (2.3) dt dA = (1 − α)σE − γ A, (2.4) dt dH = φI − δH − γ H, (2.5) dt dR = γ I + γ A + γ H, (2.6) I A H dt dD = δH, (2.7) dt where N = S + E + I + A + R, (2.8) 4 Parameter Likely range (references) Default value −1 −1 β (infectious contact rate) 0.5–1.5 day [43, 44, 38], this work 0.5 day −1 −1 σ (transition exposed to infectious) 1/14–1/3 day [19, 38] 1/5.1 day η (infectiousness factor for asymptomatic carriers) 0.4–0.6 [39, 38] 0.5 α (fraction of infections that become symptomatic) 0.15–0.7 [38, 39, 40, 49] 0.5 −1 φ (rate of hospitalization) 0.02–0.1 [35, 39] 0.025 day −1 −1 γ (recovery rate, Asymptomatic) 1/14-1/3 day [34, 35] 1/7 day −1 −1 γ (recovery rate, symptomatic) 1/30-1/3 day [34, 35] 1/7 day −1 −1 γ (recovery rate, hospitalized) [34, 35] 1/30-1/3 day 1/14 day −1 δ (death rate, hospitalized) 0.001–0.1  0.015 day Table 1: Baseline model parameters with brief description, likely ranges based on modeling and clinical studies (see text for further details), and default value chosen for this study. is the total population in the community, and β(t) is the baseline infectious contact rate, which is assumed to vary with time in general, but typically taken ﬁxed. Additionally, η accounts for the relative infectiousness of asymptomatic carriers (in comparison to symptomatic carriers), σ is the transition rate from the exposed to infectious class (so 1/σ is the disease incubation period), α is the fraction of cases that are symptomatic, φ is the rate at which symptomatic individuals are hospitalized, δ is the disease-induced death rate, and γ , γ and γ are recovery A I H rates for the subscripted population. We suppose hospitalized persons are not exposed to the general population. Thus, they are excluded from the tabulation of N, and do not contribute to infection rates in the general community. This general modeling framework is similar to a variety of SEIR-style models recently employed in [38, 39], for example. For most results in this paper, we use let β(t) ≡ β . However, given ongoing responses to the COVID-19 pandemic in terms of voluntary and mandated social distancing, etc., we also consider the possibility that β varies with time and adopt the following functional form from Tang et al. , with the modiﬁcation that contact rates do not begin declining from the initial contact rate, β , until time t , 0 0 β , t < t 0 0 β(t) = (2.9) β + (β − β ) exp(−r(t − t )), t ≥ t min 0 min 0 0 where β is the minimum contact rate and r is the rate at which contact decreases. min 2.2 Baseline epidemiological parameters The incubation period for COVID-19 is estimated to average 5.1 days , similar to other −1 model-based estimates , giving σ = 1/5.1 day . Some previous model-based estimates of infectious duration are on the order of several days [38, 39, 34], with  giving about 7 days for asymptomatic individuals to recover. However, the clinical course of the disease is typically much longer: In a study of hospitalized patients , average total duration of illness until hospital discharge or death was 21 days, and moreover, the median duration of viral shedding was 20 days in survivors. −1 The eﬀective transmission rate (as a constant), β , ranges from around 0.5 to 1.5 day in prior modeling studies [44, 43, 38], and typically trends down with time [34, 38]. We have left this as a free parameter in our ﬁts to Washington and New York state mortality data, and ﬁnd −1 β ≈ 0.5 and β ≈ 1.4 day for these states, respectively, values this range. 0 0 5 The relative infectiousness of asymptomatic carriers, η, is not known, although Ferguson et al.  estimated this parameter at about 0.5, and Li et al.  gave values of 0.42–0.55. The fraction of cases that are symptomatic, α, is also uncertain, with Li et al.  suggesting an overall case reporting rate of just 14% early in the outbreak in China, but increasing to 65–69% later; further, α = 2/3 was used in . In the case of the Diamond Princess Cruise ship , 712 (19.2%) passengers and crews tested positive for SARS-CoV-2, with 331 (46.5%) asymptomatic at the time of testing. Therefore, we choose α = 0.5 as our default. Given an average time from symptom onset to dyspnea of 7 days in , and 9 days to sepsis, a range of 1–10 days to hospitalization, a midpoint of 5 days seems reasonable (see also −1 ); φ ≈ 0.025 day is consistent with on the order of 5–15% of symptomatic patients being −1 hospitalized. If about 15% of hospitalized patients die , then δ ≈ 0.015 day (based on −1 γ = 1/14 day ). 2.2.1 Model with general mask use We assume that some fraction of the general population wears masks with uniform inward eﬃciency (i.e., primary protection against catching disease) of ǫ , and outward eﬃciency (i.e., source control/protection against transmitting disease) of ǫ . We disaggregate all population variables into those that typically do and do not wear masks, respectively subscripted with U and M. Based on the above assumptions and simpliﬁcations, the extended multi-group model for COVID-19 (where members of the general public wear masks in public) is given by: dS S S U U U = −β(I + ηA ) − β (1 − ǫ )I + (1 − ǫ )ηA , (2.10) U U o M o M dt N N dE S S U U U = β(I + ηA ) + β((1 − ǫ )I + (1 − ǫ )ηA ) − σE , (2.11) U U o M o M U dt N N dI = ασE − φI − γ I , (2.12) U U I U dt dA = (1 − α)σE − γ A , (2.13) U A U dt dH = φI − δH − γ H , (2.14) U U H U dt dR = γ I + γ A + γ H , (2.15) I U A U H U dt dD = δH , (2.16) dt dS S S M M M = −β(1 − ǫ )(I + ηA ) − β(1 − ǫ )((1 − ǫ )I + (1 − ǫ )ηA ) , (2.17) i U U i o M o M dt N N dE S S M M M = β(1 − ǫ )(I + ηA ) + β(1 − ǫ )((1 − ǫ )I + (1 − ǫ )ηA ) − σE , (2.18) i U U i o M o M M dt N N dI = ασE − φI − γ I , (2.19) M M I M dt dA = (1 − α)σE − γ A , (2.20) M A M dt dH = φI − δH − γ H , (2.21) M M H M dt dR = γ I + γ A + γ H , (2.22) I M A M H M dt dD = δH , (2.23) dt (2.24) 6 where N = S + E + I + A + R + S + E + I + A + R . (2.25) U U U U U M M M M M While much more complex than the baseline model, most of the complexity lies in what are essentially bookkeeping terms. We also consider a reduced version of the above model (equations not shown), such that only symptomatically infected persons wear a mask, to compare the consequences of the common recommendation that only those experiencing symptoms (and their immediate caretakers) wear masks with more general population coverage. 2.3 Mask eﬃciency parameters We assume a roughly linear relationship between the overall ﬁltering eﬃciency of a mask and clinical eﬃciency in terms of either inward eﬃciency (i.e., eﬀect on ǫ ) or outward eﬃciency (ǫ ), i o based on . The ﬁt factor for homemade masks averaged 2 in , while the ﬁt factor averaged 5 for surgical masks. When volunteers coughed into a mask, depending upon sampling method, the number of colony-forming units resulting varied from 17% to 50% for homemade masks and 0–30% for surgical masks, relative to no mask . Surgical masks reduced P. aeruginosa infected aerosols produced by coughing by over 80% in cystic ﬁbrosis patients in , while surgical masks reduced CFU count by >90% in a similar study . N95 masks were more eﬀective in both studies. Homemade teacloth masks had an inward eﬃciency between 58 and 77% over 3 hours of wear in , while inward eﬃciency ranged 72–85% and 98–99% for surgical and N95-equivalent masks. Outward eﬃciency was marginal for teacloth masks, and about 50–70% for medical masks. Surgical masks worn by tuberculosis patients also reduced the infectiousness of hospital ward air in , and Leung et al.  very recently observed surgical masks to decrease infectious aerosol produced by individuals with seasonal coronaviruses. Manikin studies seem to recommend masks as especially valuable under coughing conditions for both source control  and prevention . We therefore estimate that inward mask eﬃciency could range widely, anywhere from 20– 80% for cloth masks, with ≥50% possibly more typical (and higher values are possible for well-made, tightly ﬁtting masks made of optimal materials), 70–90% typical for surgical masks, and >95% typical for properly worn N95 masks. Outward mask eﬃciency could range from practically zero to over 80% for homemade masks, with 50% perhaps typical, while surgical masks and N95 masks are likely 50–90% and 70–100% outwardly protective, respectively. 2.4 Data and model ﬁtting We use state-level time series for cumulative mortality data compiled by Center for Systems Science and Engineering at Johns Hopkins University , from January 22, 2020, through April 2, 2020, to calibrate the model initial conditions and infective contact rate, β , as well as β when β(t) is taken as an explicit function of time. Other parameters are ﬁxed at default min values in Table 1. Parameter ﬁtting was performed using nonlinear least squares algorithm im- plemented using the lsqnonlin function in MATLAB. We consider two US states in particular as case studies, New York and Washington, and total population data for each state was deﬁned according to US Census data for July 1, 2019 . 7 Figure 1: Relative peak hospitalizations and cumulative mortality under simulated epidemics, −1 under either a base β = 0.5 or 1.5 day , under diﬀerent general mask coverage level and eﬃcacies (where ǫ = ǫ = ǫ). Results are relative to a base case with no mask use. The left o i half of the ﬁgure gives these metrics as two-dimensional functions of coverage and eﬃcacy. The right half gives these metrics as one-dimensional functions of coverage × eﬃcacy. 3 Results 3.1 Analytic results Closed-form expressions for the basic reproduction number, R , for the baseline model without masks and the full model with masks are given, for β(t) ≡ β , in Appendix A and B, respectively. 3.2 Masks coverage/eﬃcacy/time to adoption in simulated epidemics 3.2.1 Mask/eﬃcacy interaction under immediate adoption −1 We run simulated epidemics using either β = 0.5 or 1.5 day , with other parameters set to the defaults given in Table 1. These parameter sets give epidemic doubling times early in time (in terms of cumulative cases and deaths) of approximately seven or three days, respectively, corresponding to case and mortality doubling times observed (early in time) in Washington and New York state, respectively. We use as initial conditions a normalized population of 1 million persons, all of whom are initially susceptible, except 50 initially symptomatically infected (i.e., 5 out 100,000 is the initial infection rate), not wearing masks. We choose some fraction of the population to be initially in the masked class (“mask cov- erage”), which we also denote π, and assume ǫ = ǫ = ǫ. The epidemic is allowed to run its o i course (18 simulated months) under constant conditions, and the outcomes of interest are peak hospitalization, cumulative deaths, and total recovered. These results are normalized against the counterfactual of no mask coverage, and results are presented as heat maps in Figure 1. Note that the product ǫ× π predicts quite well the eﬀect of mask deployment: Figure 1 also shows (relative) peak hospitalizations and cumulative deaths as functions of this product. There is, however, a slight asymmetry between coverage and eﬃcacy, such that increasing coverage of moderately eﬀective masks is generally more useful than increasing the eﬀectiveness of masks from a starting point of moderate coverage. 8 ˜ Figure 2: Equivalent β , β (infectious contact rate) under baseline model dynamics as a function 0 0 of mask coverage × eﬃcacy, with the left panel giving the absolute value, and the right giving the ratio of β to the true β in the simulation with masks. That is, simulated epidemics are 0 0 run with mask coverage and eﬀectiveness ranging from 0 to 1, and the outcomes are tracked as synthetic data. The baseline model without mask dynamics is then ﬁt to this synthetic data, with β the trainable parameter; the resulting β is the β . This is done for simulated epidemics 0 0 0 −1 with a true β of 1.5, 1, or 0.5 day . 3.2.2 Delayed adoption We run the simulated epidemics described, supposing the entire population is unmasked until mass mask adoption after some discrete delay. The level of adoption is also ﬁxed as a constant. We ﬁnd that a small delay in mask adoption (without any changes in β) has little eﬀect on peak hospitalized fraction or cumulative deaths, but the “point of no return” can rapidly be crossed, if mask adoption is delayed until near the time at which the epidemic otherwise crests. This general pattern holds regardless of β , but the point of no return is further in the future for smaller β . 3.3 Mask use and equivalent β reduction The relationship between mask coverage, eﬃcacy, and metrics of epidemic severity considered above are highly nonlinear. The relationship between β (the infectious contact rate) and such metrics is similarly nonlinear. However, incremental reductions in β , due to social distances measures, etc., can ultimately synergize with other reductions to yield a meaningfully eﬀect on the epidemic. Therefore, we numerically determine what the equivalent change in β under the baseline would have been under mask use at diﬀerent coverage/eﬃcacy levels, and we denote the equivalent β value as β . 0 0 That is, we numerically simulate an epidemic with and without masks, with a ﬁxed β . Then, we ﬁt the baseline model to this (simulated) case data, yielding a new equivalent β , ˜ ˜ β . An excellent ﬁt giving β can almost always be obtained, though occasionally results are 0 0 extremely sensitive to β for high mask coverage/eﬃcacy, yielding somewhat poorer ﬁts. Results 9 Figure 3: Epidemiologic outcomes and equivalent β changes as a function of mask coverage when masks are either much better at blocking outgoing (ǫ = 0.8, ǫ = 0.2) or incoming o i (ǫ = 0.2, ǫ = 0.8) transmission. Results are demonstrated for both mask permutations under 0 i −1 simulated epidemics with baseline β = 0.5 or 1.5 day . are summarized in Figure 2, where the β values obtained and the relative changes in equivalent β (i.e., (β ) / (β )) are plotted as functions of eﬃcacy times coverage, ǫ × π, under simulated 0 0 epidemics with three baseline (true) β values. From Figure 2, we see that even 50% coverage with 50% eﬀective masks roughly halves the eﬀective disease transmission rate. Widespread adoption, say 80% coverage, of masks that are only 20% eﬀective still reduces the eﬀective transmission rate by about one-third. 3.4 Outward vs. inward eﬃciency Figure 3 demonstrates the eﬀect of mask coverage on peak hospitalizations, cumulative deaths, and equivalent β values when either ǫ = 0.2 and ǫ = 0.8, or visa versa (and for simulated 0 o i −1 epidemics using either β = 0.5 or 1.5 day . These results suggest that, all else equal, the protection masks aﬀord against acquiring infection (ǫ ) is actually slightly more important than protection against transmitting infection (ǫ ), although there is overall little meaningful asymmetry. 3.5 Masks for symptomatic alone vs. general population Finally, we consider numerical experiments where masks are given to all symptomatically in- fected persons, whether they otherwise habitually wear masks or not (i.e., both I and I U M actually wear masks). We explore how universal mask use in symptomatically infected persons interacts with mask coverage among the general population; we let ǫ represent the eﬀectiveness of masks in the symptomatic, not necessarily equal to ǫ . We again run simulated epidemics with no masks, universal masks among the symptomatic, and then compare diﬀerent levels of mask coverage in the general (asymptomatic) population. In this section, we use equivalent β as our primary metric. Figure 4 shows how this metric varies as a function of the mask eﬀectiveness given to symptomatic persons, along with the coverage and eﬀectiveness of masks 10 Figure 4: Equivalent β under the model where all symptomatic persons wear a mask (whether they otherwise habitually wear a mask or not), under varying levels of eﬀective for the masks given to the symptomatic (ǫ ), and in combination with diﬀerent degrees of coverage and eﬀec- tiveness for masks used by the rest of the general public. Results are for simulated epidemics −1 with a baseline β of 1.5 day . worn by the general public. We also explore how conclusions vary when either 25%, 50%, or 75% of infectious COVID- 19 patients are asymptomatic (i.e., we vary α). Unsurprisingly, the greater the proportion of infected people are asymptomatic, the more beneﬁt there is to giving the general public masks in addition to those experiencing symptoms. 3.6 Simulated case studies: New York & Washington states Fitting to cumulative death data, we use the baseline model to determine the best ﬁxed β and I(0) for cumulative death data for New York and Washington state. We use New York state data beginning on March 1, 2020, through April 2, 2020, and Washington state data from February 20, 2020 through April 2, 2020. For New York state, best-ﬁt parameters are I(0) = −1 208 (range 154–264) and β = 1.40 (1.35–1.46) day under ﬁxed β . For the time-varying β(t), 0 0 −1 −1 we ﬁx r = 0.03 day and t = 20, yielding a best-ﬁt β = 1.33 (1.24–1.42) day , β = 0.51 0 0 min −1 (-0.25–1.26) day , and I(0) = 293 (191–394). −1 For Washington state, parameters are I(0) = 622 (571–673) and β = 0.50 (0.49–0.52) day −1 under ﬁxed β . For time-varying β(t), we ﬁx r = 0.04 day and t = 0, to yield a best-ﬁt β 0 0 0 −1 −1 = 1.0 (0.87–1.23) day , β = 0.10 (0–0.19) day , and I(0) = 238 (177–300). min We ﬁx r and t , as it is not possible to uniquely identify r, t and β , from death or 0 0 min case data alone (see e.g.,  on identiﬁability problems). Figure 5 gives cumulative death and case data versus the model predictions for the two states, and for the two choices of β(t). Note that while modeled and actual cumulative deaths match well, model-predicted cases markedly exceed reported cases in the data, consistent with the notion of broad underreporting. We then consider either ﬁxed β or time-varying β(t), according to the parameters above, in combination with the following purely hypothetical scenarios in each state. 11 Figure 5: The left half of the ﬁgure gives model predictions and data for Washington state, using either a constant (top panels) or variable β (bottom panel), as described in the test. The right half of the ﬁgure is similar, but for New York state. Figure 6: Simulated future (cumulative) death tolls for Washington state, using either a ﬁxed (top panels) or variable (bottom panels) transmission rate, β, and nine diﬀerent permutations of general public mask coverage and eﬀectiveness. The y-axes are scaled diﬀerently in top and bottom panels. 12 Figure 7: Simulated future daily death rates for Washington state, using either a ﬁxed (top panels) or variable (bottom panels) transmission rate, β, and nine diﬀerent permutations of general public mask coverage and eﬀectiveness. The y-axes are scaled diﬀerently in top and bottom panels. Figure 8: Simulated future (cumulative) death tolls for New York state, using either a ﬁxed (top panels) or variable (bottom panels) transmission rate, β, and nine diﬀerent permutations of general public mask coverage and eﬀectiveness. 13 Figure 9: Simulated future daily death rates for New York state, using either a ﬁxed (top panels) or variable (bottom panels) transmission rate, β, and nine diﬀerent permutations of general public mask coverage and eﬀectiveness. 1. No masks, epidemic runs its course unaltered with either β(t) ≡ β ﬁxed or β(t) variable as described above. 2. The two β scenarios are considered in combination with: (1) weak, moderate, or strong deployment of masks, such that π = 0.2, 0.5, or 0.8; and (2) weak, moderate, or strong masks, such that ǫ = 0.2, 0.5, or 0.8. No masks are used up until April 2, 2020, and then these coverage levels are instantaneously imposed. This yields 18 scenarios in all (nine mask coverage/eﬃcacy scenarios, plus two underlying trends). Following the modeled imposition of masks on April 2, 2020, the scenarios are run for 60 additional simulated days. Figures 6 and 8 summarize the future modeled death toll in each city under the 18 diﬀerent scenarios, along with historical mortality data. Figures 7 and 9 show modeled daily death rates, with deaths peaking sometime in late April in New York state under all scenarios, while deaths could peak anywhere from mid-April to later than May, for Washington state. We emphasize that these are hypothetical and exploratory results, with possible death tolls varying dramatically based upon the future course of β(t). However, the results do suggest that even modestly eﬀective masks, if widely used, could help “bend the curve,” with the relative beneﬁt greater in combination with a lower baseline β or stronger underlying trend towards smaller β(t) (i.e., in Washington vs. New York). 4 Discussion & Conclusions This study aims to contribute to this debate by providing realistic insight into the community- wide impact of widespread use of face masks by members of the general population. We designed a mathematical model, parameterized using data relevant to COVID-19 transmission dynamics in two US states (New York and Washington). The model suggests a nontrivial beneﬁt to face mask use by the general public that may vary nonlinearly with mask eﬀectiveness, coverage, 14 and baseline disease transmission intensity. Face masks should be advised not just for those experiencing symptoms, and likely protect both truly healthy wearers and avoid transmission by asymptomatic carriers. The community-wide beneﬁts are greatest when mask coverage is as near universal as possible. There is considerable ongoing debate on whether to recommend general public face mask use (likely mostly homemade cloth masks or other improvised face coverings) , and while the situation is in ﬂux, more authorities are recommending public mask use, though they continue to (rightly) cite appreciable uncertainty. With this study, we hope to help inform this debate by providing insight into the potential community-wide impact of widespread face mask use by members of the general population. We have designed a mathematical model, parameter- ized using data relevant to COVID-19 transmission dynamics in two US states (New York and Washington), and our model suggests nontrivial and possibly quite strong beneﬁt to general face mask use. The population-level beneﬁt is greater the earlier masks are adopted, and at least some beneﬁt is realized across a range of epidemic intensities. Moreover, even if they have, as a sole intervention, little inﬂuence on epidemic outcomes, face masks decrease the equiva- lent eﬀective transmission rate (β in our model), and thus can stack with other interventions, including social distancing and hygienic measures especially, to ultimately drive nonlinear de- creases in epidemic mortality and healthcare system burden. It bears repeating that our model results are consistent with the idea that face masks, while no panacea, may synergize with other non-pharmaceutical control measures and should be used in combination with and not in lieu of these. Under simulated epidemics, the eﬀectiveness of face masks in altering the epidemiologic outcomes of peak hospitalization and total deaths is a highly nonlinear function of both mask eﬃcacy and coverage in the population (see Figure 1), with the product of mask eﬃcacy and coverage a good one-dimensional surrogate for the eﬀect. We have determined how mask use in the full model alters the equivalent β , denoted β , under baseline model (without masks), 0 0 ﬁnding this equivalent β to vary nearly linearly with eﬃcacy × coverage (Figure 2). Masks alone, unless they are highly eﬀective and nearly universal, may have only a small eﬀect (but still nontrivial, in terms of absolute lives saved) in more severe epidemics, such as the ongoing epidemic in New York state. However, the relative beneﬁt to general masks use may increase with other decreases in β , such that masks can synergize with other public health measures. Thus, it is important that masks not be viewed as an alternative, but as a com- plement, to other public health control measures (including non-pharmaceutical interventions, such as social distancing, self-isolation etc.). Delaying mask adoption is also detrimental. These factors together indicate that even in areas or states where the COVID-19 burden is low (e.g. the Dakotas), early aggressive action that includes face masks may pay dividends. These general conclusions are illustrated by our simulated case studies, in which we have tuned the infectious contact rate, β (either as ﬁxed β or time-varying β(t)), to cumulative mortality data for Washington and New York state through April 2, 2020, and imposed hypo- thetical mask adoption scenarios. The estimated range for β is much smaller in Washington state, consistent with this state’s much slower epidemic growth rate and doubling time. Model ﬁtting also suggests that total symptomatic cases may be dramatically undercounted in both areas, consistent with prior conclusions on the pandemic . Simulated futures for both states suggest that broad adoption of even weak masks use could help avoid many deaths, but the greatest relative death reductions are generally seen when the underlying transmission rate also falls or is low at baseline. Considering a ﬁxed transmission rate, β , 80% adoption of 20%, 50%, and 80% eﬀective masks reduces cumulative relative (absolute) mortality by 1.8% (4,419), 17% (41,317), and 55% (134,920), respectively, in New York state. In Washington state, relative (absolute) mortality 15 reductions are dramatic, amounting to 65% (22,262), 91% (31,157), and 95% (32,529). When β(t) varies with time, New York deaths reductions are 9% (21,315), 45% (103,860), and 74% (172,460), while ﬁgures for Washington are 24% (410), 41% (684), and 48% (799). In the latter case, the epidemic peaks soon even without masks. Thus, a range of outcomes are possible, but both the absolute and relative beneﬁt to weak masks can be quite large; when the relative beneﬁt is small, the absolute beneﬁt in terms of lives is still highly nontrivial. Most of our model projected mortality numbers for New York and Washington state are quite high (except for variable β(t) in Washington), and likely represent worst-case scenarios as they primarily reﬂect β values early in time. Thus, they may be dramatic overestimates, depending upon these states’ populations ongoing responses to the COVID-19 epidemics. Nevertheless, the estimated transmission values for the two states, under ﬁxed and variable β(t) represent a broad range of possible transmission dynamics, are within the range estimated in prior studies [43, 44, 38], and so we may have some conﬁdence in our general conclusions on the possible range of beneﬁts to masks. Note also that we have restricted our parameter estimation only to initial conditions and transmission parameters, owing to identiﬁability problems with more complex models and larger parameter groups (see e.g. ). For example, the same death data may be consistent with either a large β and low δ (death rate), or visa versa. Considering the subproblem of general public mask use in addition to mask use for source control by any (known) symptomatic person, we ﬁnd that general face mask use is still highly beneﬁcial (see Figure 4). Unsurprisingly, this beneﬁt is greater if a larger proportion of infected people are asymptomatic (i.e., α in the model is smaller). Moreover, it is not the case that masks are helpful exclusively when worn by asymptomatic infectious persons for source control, but provide beneﬁt when worn by (genuinely) healthy people for prevention as well. Indeed, if there is any asymmetry in outward vs. inward mask eﬀectiveness, inward eﬀectiveness is actually slightly preferred, although the direction of this asymmetry matters little with respect to overall epidemiologic outcomes. At least one experimental study  does suggest that masks may be superior at source control, especially under coughing conditions vs. normal tidal breathing and so any realized beneﬁt of masks in the population may still be more attributable to source control. This is somewhat surprising, given that ǫ appears more times than ǫ in the model terms o i giving the forces of infection, which would suggest outward eﬀectiveness to be of greater import at ﬁrst glance. Our conclusion runs counter to the notion that general public masks are primarily useful in preventing asymptomatically wearers from transmitting disease: Masks are valuable as both source control and primary prevention. This may be important to emphasize, as some people who have self-isolated for prolonged periods may reasonably believe that the chance they are asymptomatically infected is very low and therefore do not need a mask if they venture into public, whereas our results indicate they (and the public at large) still stand to beneﬁt. Our theoretical results still must be interpreted with caution, owing to a combination of potential high rates of noncompliance with mask use in the community, uncertainty with respect to the intrinsic eﬀectiveness of (especially homemade) masks at blocking respiratory droplets and/or aerosols, and even surprising amounts of uncertainty regarding the basic mechanisms for respiratory infection transmission [4, 41]. Several lines of evidence support the notion that masks can interfere with respiratory virus transmission, including clinical trials in healthcare workers [3, 4], experimental studies as reviewed [12, 10, 9, 15, 11], and case control data from the 2003 SARS epidemic [1, 2]. Given the demonstrated eﬃcacy of medical masks in healthcare workers , and their likely superiority over cloth masks in , it is clearly essential that healthcare works be prioritized when it comes to the most eﬀective medical mask supply. Fortunately, our theoretical results suggest signiﬁcant (but potentially highly variable) value even to low quality masks when used widely in the community. 16 With social distancing orders in place, essential service providers (such as retail workers, emergency services, law enforcement, etc.) represent a special category of concern, as they represent a largely unavoidable high contact node in transmission networks: Individual public- facing workers may come into contact with hundreds or thousands of people in the course of a day, in relatively close contact (e.g. cashiers). Such contact likely exposes the workers to many asymptomatic carriers, and they may in turn, if asymptomatic, expose many susceptible members of the general public to potential transmission. Air exposed to multiple infectious persons (e.g. in grocery stores) could also carry a psuedo-steady load of infectious particles, for which masks would be the only plausible prophylactic. Thus, targeted, highly eﬀective mask use by service workers may be reasonable. We are currently extending the basic model framework presented here to examine this hypothesis. In conclusion, our ﬁndings suggest that face mask use should be as nearly universal (i.e., nation-wide) as possible and implemented without delay, even if most mask are homemade and of relatively low quality. This measure could contribute greatly to controlling the COVID-19 pandemic, with the beneﬁt greatest in conjunction with other non-pharmaceutical interventions that reduce community transmission. Despite uncertainty, the potential for beneﬁt, the lack of obvious harm, and the precautionary principle lead us to strongly recommend as close to universal (homemade, unless medical masks can be used without diverting healthcare supply) mask use by the general public as possible. Acknowledgements One of the authors (ABG) acknowledge the support, in part, of the Simons Foundation (Award #585022) and the National Science Foundation (Award 1917512). Appendix A: Basic Reproduction Number for Baseline Model The basic reproduction number for both the baseline and the full model is for the special case when β(t) ≡ β . The local stability of the DFE is explored using the next generation operator method [52, 53]. Using the notation in , it follows that the matrices F of new infection terms and V of the remaining transfer terms associated with the version of the model are given, respectively, by 0 β β η 0 0 F = 0 0 0 , 0 0 0 σ 0 0 V = −ασ (φ + γ ) 0 . −(1 − α)σ 0 γ The basic reproduction number of the model, denoted by R , is given by β ασ β η(1 − α) 0 0 R = + . (4.1) σ(φ + γ ) γ I A Appendix B: Basic Reproduction Number for Full Model The local stability of the DFE is explored using the next generation operator method [52, 53]. Using the notation in , it follows that the matrices F of new infection terms and V of the 17 remaining transfer terms associated with the version of the model are given, respectively, by 0 β β η 0 β (1 − ǫ ) β (1 − ǫ )η 0 0 0 o 0 o 0 0 0 0 0 0 0 0 0 0 0 0 F = , 0 β (1 − ǫ ) β (1 − ǫ )η 0 β (1 − ǫ )(1 − ǫ ) β (1 − ǫ )(1 − ǫ )η 0 i 0 i 0 o i 0 o i 0 0 0 0 0 0 0 0 0 0 0 0 σ 0 0 0 0 0 −ασ (φ + γ ) 0 0 0 0 −(1 − α)σ 0 γ 0 0 0 V = . 0 0 0 σ 0 0 0 0 0 −ασ (φ + γ ) 0 0 0 0 −(1 − α)σ 0 γ The basic reproduction number of the model, denoted by R , is given by ασ η(1 − α) R = β [1 + (1 − ǫ )(1 − ǫ )] + . (4.2) 0 0 o i σ(φ + γ ) γ I A References  Wu, J., Xu, F., Zhou, W., Feikin, D. R., Lin, C. Y., He, X., ... & Schuchat, A. (2004). Risk factors for SARS among persons without known contact with SARS patients, Beijing, China. Emerging infectious diseases, 10(2), 210–216.  Lau, J. T., Tsui, H., Lau, M., & Yang, X. (2004). SARS transmission, risk factors, and prevention in Hong Kong. Emerging infectious diseases, 10(4), 587–592.  Oﬀeddu, V., Yung, C. F., Low, M. S. F., & Tam, C. C. (2017). Eﬀectiveness of masks and respirators against respiratory infections in healthcare workers: a systematic review and meta-analysis. Clinical Infectious Diseases, 65(11), 1934–1942.  MacIntyre, C. R., Chughtai, A. A., Rahman, B., Peng, Y., Zhang, Y., Seale, H., ... & Wang, Q. (2017). The eﬃcacy of medical masks and respirators against respiratory infection in healthcare workers. Inﬂuenza and other respiratory viruses, 11(6), 511–517.  MacIntyre, C. R., Seale, H., Dung, T. C., Hien, N. T., Nga, P. T., Chughtai, A. A., ... & Wang, Q. (2015). A cluster randomised trial of cloth masks compared with medical masks in healthcare workers. BMJ open, 5(4), e006577.  MacIntyre, C. R., Cauchemez, S., Dwyer, D. E., Seale, H., Cheung, P., Browne, G., ... & Ferguson, N. (2009). Face mask use and control of respiratory virus transmission in households. Emerging infectious diseases, 15(2),  Cowling, B. J., Chan, K. H., Fang, V. J., Cheng, C. K., Fung, R. O., Wai, W., ... & Chiu, B. C. (2009). Facemasks and hand hygiene to prevent inﬂuenza transmission in households: a cluster randomized trial. Annals of internal medicine, 151(7), 437–446.  Canini, L., Androletti, L., Ferrari, P., D’Angelo, R., Blanchon, T., Lemaitre, M., ... & Valleron, A. J. (2010). Surgical mask to prevent inﬂuenza transmission in households: a cluster randomized trial. PloS one, 5(11), e13988.  Davies, A., Thompson, K. A., Giri, K., Kafatos, G., Walker, J., & Bennett, A. (2013). Testing the eﬃcacy of homemade masks: would they protect in an inﬂuenza pandemic?. Disaster medicine and public health preparedness, 7(4), 413–418.  Lai, A. C. K., Poon, C. K. M., & Cheung, A. C. T. (2012). Eﬀectiveness of facemasks to reduce exposure hazards for airborne infections among general populations. Journal of the Royal Society Interface, 9(70), 938– 18  Patel, R. B., Skaria, S. D., Mansour, M. M., & Smaldone, G. C. (2016). Respiratory source control using a surgical mask: an in vitro study. Journal of occupational and environmental hygiene, 13(7), 569–576.  van der Sande, M., Teunis, P., & Sabel, R. (2008). Professional and home-made face masks reduce exposure to respiratory infections among the general population. PLoS One, 3(7), e2618.  Stockwell, R. E., Wood, M. E., He, C., Sherrard, L. J., Ballard, E. L., Kidd, T. J., ... & Bell, S. C. (2018). Face masks reduce the release of Pseudomonas aeruginosa cough aerosols when worn for clinically relevant periods. American journal of respiratory and critical care medicine, 198(10), 1339–1342.  Driessche, K. V., Hens, N., Tilley, P., Quon, B. S., Chilvers, M. A., de Groot, R., ... & Zlosnik, J. E. (2015). Surgical masks reduce airborne spread of Pseudomonas aeruginosa in colonized patients with cystic ﬁbrosis. American journal of respiratory and critical care medicine, 192(7), 897–899.  Dharmadhikari, A. S., Mphahlele, M., Stoltz, A., Venter, K., Mathebula, R., Masotla, T., ... & van der Walt, M. (2012). Surgical face masks worn by patients with multidrug-resistant tuberculosis: impact on infectivity of air on a hospital ward. American journal of respiratory and critical care medicine, 185(10), 1104–1109.  World Health Organization. (2020). Modes of transmission of virus causing COVID- 19: implications for IPC precaution recommendations: scientiﬁc brief, 27 March 2020 (No. WHO/2019-nCoV/Sci_Brief/Transmission_modes/2020.1).  van Doremalen, N., Bushmaker, T., Morris, D. H., Holbrook, M. G., Gamble, A., Williamson, B. N., ... & Lloyd-Smith, J. O. (2020). Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. New England Journal of Medicine.  Ong, S. W. X., Tan, Y. K., Chia, P. Y., Lee, T. H., Ng, O. T., Wong, M. S. Y., & Marimuthu, K. (2020). Air, surface environmental, and personal protective equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from a symptomatic patient. JAMA.  Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., ... & Lessler, J. (2020). The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported conﬁrmed cases: estimation and application. Annals of internal medicine. ePub ahead of print.  Wu, J. T., Leung, K., & Leung, G. M. (2020). Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. The Lancet, 395(10225), 689-697.  Calaﬁore, G. C., Novara, C., & Possieri, C. (2020). A Modiﬁed SIR Model for the COVID-19 Contagion in Italy. arXiv preprint arXiv:2003.14391.  Kucharski, A. J., Russell, T. W., Diamond, C., Liu, Y., Edmunds, J., Funk, S., ... & Davies, N. (2020). Early dynamics of transmission and control of COVID-19: a mathematical modelling study. The Lancet Infectious Diseases.  Simha, A., Prasad, R. V., & Narayana, S. (2020). A simple Stochastic SIR model for COVID 19 Infection Dynamics for Karnataka: Learning from Europe. arXiv preprint arXiv:2003.11920.  Anastassopoulou, C., Russo, L., Tsakris, A., & Siettos, C. (2020). Data-Based Analysis, Modelling and Forecasting of the novel Coronavirus (2019-nCoV) outbreak. medRxiv.  Biswas, K., Khaleque, A., & Sen, P. (2020). Covid-19 spread: Reproduction of data and prediction using a SIR model on Euclidean network. arXiv preprint arXiv:2003.07063.  Nesteruk, I. (2020). Statistics based predictions of coronavirus 2019-nCoV spreading in mainland China. MedRxiv.  Chang, S. L., Harding, N., Zachreson, C., Cliﬀ, O. M., & Prokopenko, M. (2020). Modelling transmission and control of the COVID-19 pandemic in Australia. arXiv preprint arXiv:2003.10218.  Wilder, B., Charpignon, M., Killian, J. A., Ou, H. C., Mate, A., Jabbari, S., ... & Majumder, M. S. (2020). The Role of Age Distribution and Family Structure on COVID-19 Dynamics: A Preliminary Modeling Assessment for Hubei and Lombardy. Available at SSRN 3564800.  Rothe, C., Schunk, M., Sothmann, P., Bretzel, G., Froeschl, G., Wallrauch, C., ... & Seilmaier, M. (2020). Transmission of 2019-nCoV infection from an asymptomatic contact in Germany. New England Journal of Medicine.  Ruiz Estrada, M. A., & Koutronas, E. (2020). The Networks Infection Contagious Diseases Positioning System (NICDP-System): The Case of Wuhan-COVID-19. Available at SSRN 3548413.  Dehning, J., Zierenberg, J., Spitzner, F. P., Wibral M., Neto, J. P., Wilczek, M., & Priesemann, V. (2020). Inferring COVID-19 spreading rates and potential change points for case number forecasts. arXiv preprint arXiv:2004.01105. 19  Zhang, Y., Yu, X., Sun, H., Tick, G. R., Wei, W., & Jin, B. (2020). COVID-19 infection and recovery in various countries: Modeling the dynamics and evaluating the non-pharmaceutical mitigation scenarios. arXiv preprint arXiv:2003.13901.  Moore, S. E., & Okyere, E. Controlling the transmission dynamics of COVID-19. arXiv preprint arXiv:2004.00443.  Tang, B., Bragazzi, N. L., Li, Q., Tang, S., Xiao, Y., & Wu, J. (2020). An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov). Infectious Disease Modelling, 5, 248–255.  Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., ... & Guan, L. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet.  Brienen, N. C., Timen, A., Wallinga, J., Van Steenbergen, J. E., & Teunis, P. F. (2010). The eﬀect of mask use on the spread of inﬂuenza during a pandemic. Risk Analysis: An International Journal, 30(8), 1210–1218.  Tracht, S. M., Del Valle, S. Y., & Hyman, J. M. (2010). Mathematical modeling of the eﬀectiveness of facemasks in reducing the spread of novel inﬂuenza A (H1N1). PloS one, 5(2).  Li, R., Pei, S., Chen, B., Song, Y., Zhang, T., Yang, W., & Shaman, J. (2020). Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). Science.  Ferguson, N., Laydon, D., Nedjati Gilani, G., Imai, N., Ainslie, K., Baguelin, M., ... & Dighe, A. (2020). Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand.  Verity, R., Okell, L. C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., ... & Dighe, A. (2020). Estimates of the severity of coronavirus disease 2019: a model-based analysis. The Lancet Infectious Diseases.  Bourouiba, L. (2020). Turbulent Gas Clouds and Respiratory Pathogen Emissions: Potential Implications for Reducing Transmission of COVID-19. JAMA.  Leung, N. H., Chu, D. K., Shiu, E. Y., Chan, K. H., McDevitt, J. J., Hau, B. J., ... & Seto, W. H. Respiratory Virus Shedding in Exhaled Breath and Eﬃcacy of Face Masks. Nature Medicine.  Shen, M., Peng, Z., Xiao, Y., & Zhang, L. (2020). Modelling the epidemic trend of the 2019 novel coronavirus outbreak in China. bioRxiv. The baseline model parameters are listed in Table 1, with approximate ranges from the literature based on both clinical and modeling studies, as discussed here.  Read, J. M., Bridgen, J. R., Cummings, D. A., Ho, A., & Jewell, C. P. (2020). Novel coronavirus 2019-nCoV: early estimation of epidemiological parameters and epidemic predictions. MedRxiv.  Han, Q., Lin, Q., Ni, Z., & You, L. (2020). Uncertainties about the transmission routes of 2019 novel coronavirus. Inﬂuenza and Other Respiratory Viruses.  Roda, W. C., Varughese, M. B., Han, D., & Li, M. Y. (2020). Why is it diﬃcult to accurately predict the COVID-19 epidemic?. Infectious Disease Modelling.  Center for Systems Science and Engineering at Johns Hopkins University. (2020). COVID-19. Github Repos- itory. https://github.com/CSSEGISandData/COVID-19. Last accessed April 2, 2020.  US Census. Annual Estimates of the Resident Population for the United States, Re- gions, States, and Puerto Rico: April 1, 2010 to July 1, 2019 (NST-EST2019-01). https://www.census.gov/data/tables/time-series/demo/popest/2010s-state-total.html#par_textimage_1574439295. Accessed April 2, 2020.  Moriarty, L. F. (2020). Public Health Responses to COVID-19 Outbreaks on Cruise ShipsWorldwide, Febru- aryMarch 2020. MMWR. Morbidity and Mortality Weekly Report, 69.  Wang, C. J., Ng, C. Y., & Brook, R. H. (2020). Response to COVID-19 in Taiwan: big data analytics, new technology, and proactive testing. JAMA.  Chan, K. H., & Yuen, K. Y. (2020). COVID-19 epidemic: disentangling the re-emerging controversy about medical facemasks from an epidemiological perspective. International Journal of Epidemiology.  Diekmann, O., Heesterbeek, J. A. P., & Metz, J. A. (1990). On the deﬁnition and the computation of the basic reproduction ratio R in models for infectious diseases in heterogeneous populations. Journal of mathematical biology, 28(4), 365–382.  van den Driessche, P., & Watmough, J. (2002). Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission. Mathematical biosciences, 180(1-2), 29–48.
Quantitative Biology – arXiv (Cornell University)
Published: Apr 7, 2020
Access the full text.
Sign up today, get DeepDyve free for 14 days.